Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated via claimed linking group – bond – chelating agent,...
Reexamination Certificate
2008-02-01
2011-11-15
Romeo, David (Department: 1647)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated via claimed linking group, bond, chelating agent,...
C424S188100, C530S391900
Reexamination Certificate
active
08057798
ABSTRACT:
The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
REFERENCES:
patent: 3791932 (1974-02-01), Schuurs et al.
patent: 3949064 (1976-04-01), Bornstein et al.
patent: 4174384 (1979-11-01), Ullman et al.
patent: 4554101 (1985-11-01), Hopp
patent: 5738985 (1998-04-01), Miles et al.
patent: 6277959 (2001-08-01), Valladeau et al.
patent: 6451995 (2002-09-01), Cheung et al.
patent: 6541011 (2003-04-01), Punnonen et al.
patent: 2005/0037001 (2005-02-01), Germeraad et al.
patent: 2005/0106700 (2005-05-01), Nomura et al.
patent: 2008/097817 (2008-08-01), None
Wiley et al. The in-vitro inhibition of rat alloantigen presentation by immunotoxins—implications for allografting. Clin Exp Immunol. Apr. 1989;76(1):132-7.
Huang et al. Cloning and characterization of a novel ITIM containing lectin-like immunoreceptor LLIR and its two transmembrane region deletion variants. Biochem Biophys Res Commun. Feb. 16, 2001;281(1):131-40.
Marks et al. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol. Dec. 5, 1991;222(3):581-97.
Smith et al. Lack of dendritic cell maturation by the plant toxin ricin. Eur J Immunol. Aug. 2004;34(8):2149-57.
Spooner et al. Expression of immunoglobulin heavy chain-ricin A chain fusions in mammalian cells. Mol Immunol. Feb. 1994;31(2):117-25, Abstract only.
International Search Report and Written Opinion for PCT/US2008/052850 dated Sep. 24, 2008.
Figdor, Carl A., “C-Type Lectin Receptors on Dendritic Cells and Langerhans Cells.” Nature Reviews. Feb. 2002. 2:77-84.
Banchereau, J., et al., “Immunobiology of dendritic cells.” Annu Rev Immunol (2000), 18: 767-811.
Banchereau, J., et al., “Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.” Cancer Res (2001), 61(17): 6451-8.
Banchereau, J., et al., “Dendritic cells as vectors for therapy.” Cell (2001), 106(3): 271-4.
Bates, E. E., et al., “APCs express DCIR, a novel C-type lectin surface receptor containing an immunoreceptor tyrosine-based inhibitory motif.” J Immunol (1999), 163(4): 1973-83.
Bendtsen, J. D., et al., “Improved prediction of signal peptides: SignalP 3.0.” J Mol Biol (2004), 340(4): 783-95.
Berard, F., et al., “Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.” J Exp Med (2000), 192(11): 1535-44.
Bonifaz, L. C., et al., “In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination.” J Exp Med (2004), 199(6): 815-24.
Carvalho, A. L., et al., “Cellulosome assembly revealed by the crystal structure of the cohesin-dockerin complex.” Proc Natl Acad Sci U S A (2003), 100(24): 13809-14.
Deineste, Y., G. et al., “Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation.” Immunity (2002), 17(3): 353-62.
Figdor, C. G., et al., “C-type lectin receptors on dendritic cells and Langerhans cells.” Nat Rev Immunol (2002), 2(2): 77-84.
Geijtenbeek, T. B., et al., “Self- and nonself-recognition by C-type lectins on dendritic cells.” Annu Rev Immunol (2004), 22: 33-54.
Mellman, I. et al., “Dendritic cells: specialized and regulated antigen processing machines.” Cell (2001), 106(3): 255-8.
Neidhardt-Berard, E. M., et al., “Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes.” Breast Cancer Res (2004), 6(4): R322-8.
Palucka, A. K., et al., “Human dendritic cell subsets in NOD/SCID mice engrafted with CD34+ hematopoietic progenitors.” Blood (2003), 102(9): 3302-10.
Ramakrishna, V., et al., “Mannose receptor targeting of tumor antigen pme117 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules.” J Immunol (2004), 172(5): 2845-52.
Reddy, M. P., et al., “Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4.” J Immunol (2000), 164(4): 1925-33.
Shortman, K. et al., “Mouse and human dendritic cell subtypes.” Nat Rev Immunol (2002), 2(3): 151-61.
Steinman, R. M. et al., “Active immunization against cancer with dendritic cells: the near future.” Int J Cancer (2001), 94(4): 459-73.
Tacken, P. J., et al., “Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody.” Blood (2005), 106(4): 1278-85.
Trombetta, E. S. et al., “Cell biology of antigen processing in vitro and in vivo.” Annu Rev Immunol (2005), 23: 975-1028.
Trumpfheller, C., et al. (2006). “Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine.” J Exp Med (2006), 203(3): 607-17.
Extended European Search Report for EP 08 72 8868 dated Aug. 3, 2010.
Craig, S.J., et al., “Engineered proteins containing the cohesin and dockerin domains fromClostridium thermocellumprovides a reversible, high affinity interaction for biotechnology applications,” Journal of Biotechnology (2006), Jan. 24, 2006.
Banchereau Jacques F.
Flamar Anne-Laure
Klechevsky Eynav
Zurawski Gerald
Zurawski Sandra
Baylor Research Institute
Chalker Flores LLP
Flores Edwin S.
Romeo David
Singleton Chainey P.
LandOfFree
Vaccines based on targeting antigen to DCIR expressed on... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccines based on targeting antigen to DCIR expressed on..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccines based on targeting antigen to DCIR expressed on... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4256175